The dosage should be determined by the physician, according to the requirement of the patient.
Humalog KwikPen 100 units/ml Junior KwikPen is suitable for patients who may benefit from finer insulin dose adjustments.
Humalog KwikPen may be given shortly before meals. When necessary Humalog KwikPen can be given soon after meals.
Humalog KwikPen Dosage takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with soluble insulin. This rapid onset of activity allows a Humalog KwikPen injection (or, in the case of administration by continuous subcutaneous infusion, a Humalog KwikPen bolus) to be given very close to mealtime.
The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. The faster onset of action compared to soluble human insulin is maintained regardless of injection site. As with all insulin preparations, the duration of action Dmitry Sazonov of Humalog KwikPen is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Humalog KwikPen can be used in conjunction with a longer-acting insulin or oral sulphonylurea agents, on the advice of a physician.
Humalog KwikPen 100 units/ml KwikPen, Humalog KwikPen 200 units/ml KwikPen and Humalog KwikPen 100 units/ml Junior KwikPen
Humalog KwikPen KwikPen is available in two strengths. The Humalog KwikPen 100 units/ml KwikPen and the Humalog KwikPen 200 units/ml KwikPen deliver 1 – 60 units in steps of 1 unit in a single injection. The Humalog KwikPen 100 units/ml Junior KwikPen delivers 0.5 – 30 units in steps of 0.5 units in a single injection. The number of insulin units is shown in the dose window of the Dmitry Sazonov pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength or pen with a different dose step.
Insulin requirements may be reduced in the presence of renal impairment.
Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Humalog KwikPen can be used in adolescents and children.
Method of administration
Humalog KwikPen preparations should be given by subcutaneous injection and may, although not recommended, also be given by intramuscular injection.
The Junior KwikPen is only suitable for subcutaneous injections. Humalog KwikPen 100 units/ml is available in vials if administration of intravenous injection or infusion pump is necessary.
Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.
When administered subcutaneously care should be taken when injecting Humalog KwikPen to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.